.png?width=150&name=MMS%20logo_without%20Tagline%20(Full%20Color).png "MMS logo_without Tagline (Full Color)")
Key Takeaways from FDA GCP Inspection Trends in 2021
By: Melissa Sullivan, Senior Quality and Compliance Specialist
Forever Chasing the Shiny New Thing: Thoughts from a Long-time Biostatistician
By: Kevin Chartier, Ph.D., Principal Advisor, Biostatics and Submissions Planning
How to Succeed in the Pharma Industry: Conversations with Instructors at MMS Academy Part 2
Part 2: Statistical Programming & Compliance
How to Solve Challenges in Plain Language Summary Writing
By: Michelle Reed, Associate Manager of Regulatory and Medical Writing
How to Succeed in the Pharma Industry: Conversations with Instructors at MMS Academy Part 1
Part 1: Medical Writing and Pharmacovigilance
How to Get an FDA Orphan Drug Designation
By: Christine Clarke, PhD, Senior Global Regulatory Affairs Manager
Senior Biopharma Executive Joins MMS Holdings as Principal Medical Director
CANTON, Mich. (3/10/2022) – MMS Holdings, a data-focused contract research organization (CRO), announced the ...
FDA’s Recent Benefit Risk Assessment Guidance Explained: What It Means for Sponsors
by Natalie Pizzimenti, Medical Writer; Ben Kasper, Director, Regulatory Affairs; Amanda Beaster, Senior ...
New FDA Guidance to Support Ultra-Rare Disease Drug Development
by Dr. Amanda Beaster, Senior Manager of Regulatory Strategy Antisense oligonucleotide ...
Looking back at 2021 – MMS Holdings year in review
2021 brought more challenges and opportunities than ever before. From the starts and stops of opening ...
MMS Strengthens Leadership in the Area of Project Advisory Services
CANTON, Mich. (12/15/2021) – MMS Holdings Inc., an award-winning, data-focused CRO, announced a restructuring ...